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Abstract  
The nuclear export protein of Influenza A Virus is a multifunctional protein. The nuclear export protein of 
Influenza A Virus play imperative roles in the virus life cycle. The objective of the present study was to identify 
the ivermectin drug binding sites in the C-terminal domain of nuclear export protein of Influenza A Virus. The 
study was based on the experimental protein structure of C-terminal domain (residues 63-116) of nuclear export 
protein. On the whole, this study exposed four novel ivermectin binding sites in the functional regions of the 
C-terminal region of the protein. In conjunction with the conservational analysis of nuclear export protein 
which was previously determined, binding site 1 was found to be completely conserved, whereas the rest of the 
binding sites showed varied level of conservation. Therefore ivermectin targeting these drug binding sites is 
less likely to become ineffective due to drug resistance in the future. This makes IVM an effective and efficient 
anti-NEP drug. 
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6Introduction 
Influenza virus belongs to orthomyxoviridae family, which is enveloped with negative sense RNA 
genome. A, B and C are major serotypes of influenza virus [1]. Influenza A Virus (IAV) with its global 
dominance is a significant pathogen among the three serotypes [1]. IAV is responsible for 250,000 to 
500,000 human deaths worldwide [2] and also results in considerable losses among domesticated birds [3]. 
IAV is responsible for five devastating pandemics in the years 1918/1919, 1957, 1968, 1977 and 2009 
[4-8]. Apart from these pandemics, IAV also causes seasonal epidemics with moderate severity. When a 
pathogenic IAV of animal or avian origin attains the potential of efficient human-human transmission, 
then influenza pandemics seems to arise [9, 10]. This potential can be accomplished either by an event of 
mutation or by reassortment of viral RNA segments between animal/avian and human viruses [9, 10].  In 
the recent past, pathogenic avian influenza viruses namely, H5N1, H6N1, H7N7, H9N2 and H10N7 have 
acquired the ability to infect humans [11]. Therefore, in the future it is highly likely that a novel avian 
IAV will acquire the potential to transmit efficiently among humans and results in a devastating pandemic. 
Vaccines and antivirals are available against annual epidemics caused by IAV. But these are rendered 
ineffective against antiviral resistant strains of IAV emerging in the future, which is a cause of concern 
[12]. While attempts are underway to develop antivirals and vaccines which are universally applicable 
and which does not lead to resistance. 
Viral neucleocapside of IAV consists of eight separate segments and segment eight encodes two 
proteins namely, non-structural protein 1 (NS1) and non-structural protein 2 (NS2) which is also known 
as nuclear export protein (NEP) [1]. NEP (MW = 15kDa) is a multifunctional protein with 121 amino acid 
residues [13]. The important function of NEP is its role in mediating the export of viral ribonucleoprotein 
(vRNP) from host nucleus to the cytoplasm [14]. NEP is additionally involved in (i) viral assembly 
through NEP-M1 interactions [15]; (ii) viral budding via interaction with host cell ATPase [16]; (iii) 
regulation of cellular accumulation of IAV’s mRNA, cRNA and vRNA, resulting in switching from 
transcription of viral RNA to production vRNPs [17]. NEP consists of two domains namely, N-terminal 
domain (NTD; 1-53 residues) and C-terminal domain (CTD; 54-121 residues) [18]. Structural information 
is available only for CTD region 63-116 amino acids [18], while NTD resisted all efforts to crystallize. 
Recently Shimizu et al. have demonstrated that CTD is essential for both M1 protein binding as well as 
for vRNP nuclear export [19]. Previously Darapaneni et al. have identified several universally conserved 
residues of NEP namely, Met1, Thr5, Ser8–Gln10, Ile12, Arg15–Ser17, Lys18, Gln20, Leu21, Ser24, 
Ser25, Leu28, Gly30, Thr33, Ser37, Leu38, Tyr41–Asp43, Leu45, Gly46, Met50, Arg51, Gly53, Asp54, 
Gln59, Arg61, Asn62, Trp65, Arg66, Leu69, Lys72–Glu75, Arg77–Ile80, Gly82, Arg84, Leu87, Thr90, 
Glu91, Ser93–Phe99, Gln101–Leu106, Glu108– Glu110, Glu112, Arg114, Ser117, Gln119, Ile121 [20].  
Ivermectin (IVM) is an antibiotic obtained from Streptomyces avermectinius, with a molecular weight 
of 874g/mol and is a neutral molecule which has poor solubility in water [21]. IVM is known to be 
effective against ecto- and endoparasites [22]. Wagstaff et al. demonstrated that IVM can inhibit 
replication of human immunodeficiency virus-1 and dengue virus by inhibiting the nuclear import 
machinery [23]. Recently Nguyen et al. have showed that IVM can block nuclear localization signal of 
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parvovirus [24]. Due to the fact that NEP is also involved in nuclear export of vRNP [19], this makes 
NEP a potential target of IVM. The aim of the present study is to detect binding sites of IVM on the 
influenza NEP.  
Methods 
Protein structure  
The experimental structure of NEP from IAV was obtained from protein data bank (PDB) [25] with 
PDB-ID 1PD3 [18]. The structure coordinate file was split manually into a monomer and chain A (63-116 
amino acids) was selected.   
IVM binding site analysis 
Potential IVM binding sites were identified on the protein structure of NEP using COFACTOR 
(http://zhanglab.ccmb.med.umichedu/COFACTOR/) algorithm by submitting PDB structure file of NEP 
as an input [26-28]. COFACTOR algorithm identifies the ligand binding sites using both global and local 
alignments with templates from PDB and match local motifs of the identified template with that of query 
structure [26-28].  
Results  
NEP protein structure 
The obtained experimental structure of NEP consists of two α-helices namely, α-helix 1 (residues 65-85) 
and α-helix 2 (residues 94-115). Both the helices are equivalent in length joined by a short inter-helical 
turn of length eight residues (residues 86-93). 
IVM binding sites 
COFACTOR algorithm [26-28] has identified four potential IVM binding sites on the CTD of NEP and is 
shown in the table 1. The IVM binding site 1, IVM binding site 3 and IVM binding site 4 were found to 
be entirely located in the α-helix 2, while the IVM binding site 2 was found to span the two helices i.e., 
α-helix 1 and α-helix 2 of the CTD of the protein. All the four IVM binding sites detected by the 
COFACTOR [26-28] are shown along with residue conservation obtained from the study of Darapaneni et 
al. [20] in the Figure 1. 
 




Figure 1 IVM binding sites detected by COFACTOR algorithm [26-28]. IVM is shown in green. The conserved and 
variable residues are shown in maroon and turquoise respectively obtained from the study of Darapaneni et al. [20] 
 
Table 1 Potential IVM binding sites detected by the COFACTOR algorithm [26-28] 
Binding site Residues in the binding site Drug 
1 Phe99, Ala102, Leu103, Leu106 IVM  
2 Glu81, Arg84, Gln96, Phe99, Met100, Leu103, Gln104, Leu107 IVM 
3 Glu75, ILE76, ARG77, ILE80, GLU81, ARG84 IVM 
4 Gln71, Lys72, Glu75, Ile76, Leu79, Glu82 IVM 
 
Discussion 
The objective of the present study was to determine the potential binding sites of the drug IVM in the 
CTD of the IAV NEP. The protein model used in this study was the experimental structure obtained by 
Akarsu et al. using X-ray diffraction experiment [18]. A total of four potential IVM binding sites were 
detected by the COFACTOR algorithm [26-28]. Thus obtained binding sites were studied in conjunction 
with results of conservational analysis done by Darapaneni et al. [20] 
Binding site 1 was found to be conserved, as all the residues which line the binding site of the drug 
were found to be conserved among different strains of IAV from different hosts. Therefore, targeting this 
site with the drug IVM will not lead to resistance as a result of high degree of residue conservation. 
Binding site 2 was found to contain residues of various degree of conservation. Residues Arg84, Gln96, 
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Phe99, Leu103 and Gln104 were found to be conserved; residue Leu107 was found to be variable, while 
Glu81 and Met100 were intermediately conserved. Binding site 3 and binding site 4 were found to have 
the same degree of conservation. In binding site 3, apart from Ile76 and Glu81 which are intermediately 
conserved, all the other amino acid residues were found to be conserved. In binding site 4, with the 
exception of Glu71 and Ile76 which are intermediately conserved, all the other amino acid residues were 
found to be conserved. Therefore, targeting binding site 2, binding site 3 and binding site 4 with the drug 
IVM will not lead to resistance as a result of conserved residues which line these binding sites.    
The IVM drug binding sites identified in this study are located in the region which is implicated in the 
export of vRNP, NEP-M1 binding as well as stabilizing the NEP structure [18, 19]. Therefore targeting 
these sites with IVM will interfere and abolish both export of vRNP and NEP-M1 protein binding, which 
in turn result in disruption of infective lifecycle of IAV. Targeting these sites with IVM will also 
destabilize the protein structure of NEP as it will interfere with the structure stabilizing covalent bonds 
[18]. 
Conclusion 
In conclusion, the analysis of NEP CTD protein structure revealed novel IVM drug binding sites. The 
identified IVM binding sites displayed higher level of conservation among the residues which line them. 
Therefore IVM targeting these conserved sites is less likely to become ineffective due to drug resistance 
in the future. This makes IVM an effective and efficient anti-NEP drug. 
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